Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 1
2005 3
2006 1
2007 3
2009 2
2010 3
2011 4
2012 1
2013 9
2014 10
2015 19
2016 33
2017 32
2018 32
2019 36
2020 31
2021 45
2022 42
2023 62
2024 41
2025 64
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Results by year

Filters applied: . Clear all
Page 1
Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial.
Okazaki S, Tanaka K, Yazawa Y, Doijiri R, Koga M, Ihara M, Yamamoto S, Kamiyama K, Honda Y, Uchida K, Yoshimoto T, Asakura K, Omae K, Tanaka K, Maeda H, Yamamoto H, Hirano T, Toyoda K, Iguchi Y, Noguchi T, Okada Y, Kitagawa K, Sakai N, Yamagami H; ATIS-NVAF Trial Investigators. Okazaki S, et al. Among authors: noguchi t. JAMA Neurol. 2025 Dec 1;82(12):1227-1234. doi: 10.1001/jamaneurol.2025.3662. JAMA Neurol. 2025. PMID: 41051787 Clinical Trial.
IMPORTANCE: Patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease are at an elevated risk of recurrent ischemic events. Although combined anticoagulant and antiplatelet therapy may reduce ischemic risk, it a …
IMPORTANCE: Patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease a …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. ...The primary efficacy end point was a composite of nonfatal myocardial i …
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would …
Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals.
Kataoka Y, Ray KK, Nicholls SJ, Katasako-Yabumoto A, Kitahara S, Hosoda H, Mitsui K, Murai K, Sawada K, Matama H, Iwai T, Honda S, Fujino M, Yoneda S, Nakao K, Takagi K, Asaumi Y, Noguchi T. Kataoka Y, et al. Among authors: noguchi t. Eur Heart J. 2026 May 24:ehag446. doi: 10.1093/eurheartj/ehag446. Online ahead of print. Eur Heart J. 2026. PMID: 42177636 Free article.
METHODS: Multicentre retrospective observational study analysing 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of major adverse cardiovascular events (MACE) (cardiac death + non-fatal myocardial infarction + coronary revascularization in non-culprit s …
METHODS: Multicentre retrospective observational study analysing 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of majo …
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Ono K, Kadota K, Suwa S, Morishima I, Yoshida R, Hata Y, Akao M, Yagi M, Suematsu N, Morino Y, Yokomatsu T, Takamisawa I, Noda T, Doi M, Okayama H, Nakamura Y, Hibi K, Sakamoto H, Noguchi T, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. Among authors: noguchi t. J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Free article. Clinical Trial.
The primary endpoint was a composite of cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis) or major bleeding (TIMI major or minor bleeding). ...By the 1-year landmark analysis, clopidogrel was numerically, but …
The primary endpoint was a composite of cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, or defin …
Author's reply.
Fujino M, Aikawa H, Noguchi T. Fujino M, et al. Among authors: noguchi t. J Cardiol. 2024 Jan;83(1):65-66. doi: 10.1016/j.jjcc.2023.07.009. Epub 2023 Jul 29. J Cardiol. 2024. PMID: 37517606 Free article. No abstract available.
JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction.
Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, Matsuzawa Y, Mitsutake Y, Mitani Y, Murohara T, Noda T, Node K, Noguchi T, Suzuki H, Takahashi J, Tanabe Y, Tanaka A, Tanaka N, Teragawa H, Yasu T, Yoshimura M, Asaumi Y, Godo S, Ikenaga H, Imanaka T, Ishibashi K, Ishii M, Ishihara T, Matsuura Y, Miura H, Nakano Y, Ogawa T, Shiroto T, Soejima H, Takagi R, Tanaka A, Tanaka A, Taruya A, Tsuda E, Wakabayashi K, Yokoi K, Minamino T, Nakagawa Y, Sueda S, Shimokawa H, Ogawa H; Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. Hokimoto S, et al. Among authors: noguchi t. Circ J. 2023 May 25;87(6):879-936. doi: 10.1253/circj.CJ-22-0779. Epub 2023 Apr 6. Circ J. 2023. PMID: 36908169 Free article. No abstract available.
Associations among cardiovascular and cerebrovascular diseases: Analysis of the nationwide claims-based JROAD-DPC dataset.
Nakai M, Iwanaga Y, Sumita Y, Wada S, Hiramatsu H, Iihara K, Kohro T, Komuro I, Kuroda T, Matoba T, Nakayama M, Nishimura K, Noguchi T, Takemura T, Tominaga T, Toyoda K, Tsujita K, Yasuda S, Miyamoto Y, Ogawa H. Nakai M, et al. Among authors: noguchi t. PLoS One. 2022 Mar 11;17(3):e0264390. doi: 10.1371/journal.pone.0264390. eCollection 2022. PLoS One. 2022. PMID: 35275919 Free PMC article.
Cardiovascular diseases were defined as myocardial infarction, heart failure, atrial fibrillation, and aortic dissection. ...More intensive prevention and management of cardiovascular and cerebrovascular disease might be crucial....
Cardiovascular diseases were defined as myocardial infarction, heart failure, atrial fibrillation, and aortic dissection. ...More int …
Noninvasive Coronary Plaque Imaging.
Noguchi T, Nakao K, Asaumi Y, Morita Y, Otsuka F, Kataoka Y, Hosoda H, Miura H, Fukuda T, Yasuda S. Noguchi T, et al. J Atheroscler Thromb. 2018 Apr 1;25(4):281-293. doi: 10.5551/jat.RV17019. Epub 2017 Dec 9. J Atheroscler Thromb. 2018. PMID: 29225326 Free PMC article. Review.
Early identification of high-risk or vulnerable atherosclerotic plaques prone to rupture and performing preemptive therapy prior to catastrophic cardiovascular events are optimal goals of plaque imaging. Despite the advances in imaging modalities to identify vulnerable cha …
Early identification of high-risk or vulnerable atherosclerotic plaques prone to rupture and performing preemptive therapy prior to catastro …
Diagnosis and treatment of cardiovascular disease in patients with heritable connective tissue disorders or heritable thoracic aortic diseases.
Yagyu T, Noguchi T. Yagyu T, et al. Among authors: noguchi t. Cardiovasc Interv Ther. 2024 Apr;39(2):126-136. doi: 10.1007/s12928-023-00977-0. Epub 2024 Jan 5. Cardiovasc Interv Ther. 2024. PMID: 38182694 Review.
This review provides an overview of the diagnosis and treatment of HCTDs/HTADs, including current evidence on cardiovascular interventions for this population....
This review provides an overview of the diagnosis and treatment of HCTDs/HTADs, including current evidence on cardiovascular interven …
Acute Aortic Dissection in Progressively Aging Societies.
Yagyu T, Noguchi T. Yagyu T, et al. Among authors: noguchi t. Circ J. 2024 Feb 22;88(3):307-308. doi: 10.1253/circj.CJ-23-0695. Epub 2023 Oct 24. Circ J. 2024. PMID: 37880101 Free article. No abstract available.
426 results